Influence of vitamin B12 on homocysteine level in patients with comorbid course of coronary heart disease and gastrointestinal acid-related diseases

Authors

  • V. F. Orlovskiy
  • A. V. Zharkova

DOI:

https://doi.org/10.14739/2310-1210.2012.6.18321

Keywords:

vitamin B12, homocysteine, ischemic heart disease, acid peptic disease, proton pump inhibitors

Abstract

Present article is devoted to the study of the correlation between vitamin B12 serum level and hyperhomocysteinaemia. In agreement with the literature, we found signifi cant inverse relationships between vitamin B12 and homocysteine plasma levels. During research it was discovered that the lowest vitamin B12 serum level and the homocysteine serum level have been registrated in patients having associated pathology (ischemic heart disease and acid peptic disease according to long-term proton pump inhibitor use).Evident correlation was shown between that changes and the term of proton pump inhibitor use. Parenteral B12  upplementation reduces circulating homocysteine concentration and decreases risk of coronary events in рatients with comorbidity of ischemic heart disease and acid peptic disease.

References

Бабак О.Я. Сравнительная характеристика клинической

эффективности рабепразола и других ингибиторов протонной помпы по результатам мета-анализа / О.Я. Бабак //Сучасна гастроентерологія. – 2007. – №3 (35). – С. 32–37.

Буряк В.В. Ліпідний спектр та вміст гомоцистеїну у хворих з артеріальною гіпертензією, асоційованою з патологією екстракраніальних артерій: автореф. дис. … канд. мед. наук: спец 14.01.11 «Кардіологія» / В.В. Буряк. – Запоріжжя, 2011. – 20 [1] с.

Нестеров Ю.И. Атеросклероз: диагностика, лечение, профилактика / Ю.И. Нестеров. – Ростов-на-Дону: Феникс,

– 255 с.

Соболева Е.В. Гомоцистеинемия в патогенезе ишемической болезни сердца. Плеотропные эффекты статинов / Е.В. Соболева, П.А. Лебедев // Вестник СамГУ. – 2007. – №2 (52). – С. 242–255.

Янг У.К. Безопасность лечения ингибиторами протонной помпы / У.К. Янг, Д.С. Мец // Клиническая Гастроэнтерология и Гепатология. Русское издание. – 2010. – Т. 3, №6. – С. 342–353.

Abraham J.M. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? / J.M. Abraham, L. Cho // Cleve Clin. J. Med. – 2010. – Vol. 77, №12. – P. 911–918.

Ali T. Long-term Safety Concerns with Proton Pump Inhibitors / T. Ali, D.N. Roberts, W.M. Tierney // Am. J. Med. – 2009. – Vol. 122, №10. – P. 196–203.

Carmel R. Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications,and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II / R. Carmel //Am. J. Clin. Nutr.– 2011. – Vol. 94, №1. – P. 348–358.

Deshmukh U.S. Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo–сontrolled, double– blind trial in India / U.S. Deshmukh, C.V. Joglekar, H.G. Lubree et al. // Eur. J. Clin. Nutr. – 2010. – Vol. 64, №5. – P. 495–502.

Elzen W.P.J. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals / W.P.J. den Elzen, Y. Groeneveld, V. de Ruijter // Alimentary Pharmacology and Therapeutic Journal. – 2008. – Vol. 27. – P. 491–497.

Nexo E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility / E. Nexo, E. Hoffmann-Lücke // Am. J. Clin. Nutr. – 2011. – Vol. 94, №1. – P. 359–365.

Vannucchi H. Hyperhomocysteinemia and cardiometabolic risk / H. Vannucchi, S.S. Melo // Arq. Bras. Endocrinol. Metabol. – 2009. – Vol. 53, №5. – P. 540–549

Downloads

How to Cite

1.
Orlovskiy VF, Zharkova AV. Influence of vitamin B12 on homocysteine level in patients with comorbid course of coronary heart disease and gastrointestinal acid-related diseases. Zaporozhye Medical Journal [Internet]. 2013Oct.22 [cited 2024Nov.15];(6). Available from: http://zmj.zsmu.edu.ua/article/view/18321

Issue

No. 6 (2012)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)